CELMOD
DEAD

Serial Number

97367616

Owner

BRISTOL-MYERS SQUIBB COMPANY

Attorney

Xiomara Triana

First Use Date

Jun 28, 2024

Filing Date

Apr 18, 2022

Add to watchlist:

No watchlists yet
View on USPTO

CELMOD Trademark

Serial Number: 97367616

CELMOD is a trademark filed by BRISTOL-MYERS SQUIBB COMPANY on April 18, 2022. The trademark is classified under Class 5 (Pharmaceuticals). The application is currently no longer active.

Owner Contact Info

BRISTOL-MYERS SQUIBB COMPANY (4,762 trademarks)

NEW YORK, NY 10154

Entity Type: 03

Trademark Details

Filing Date

April 18, 2022

Registration Date

Not Registered

First Use Anywhere

June 28, 2024

First Use in Commerce

June 28, 2024

Published for Opposition

May 16, 2023

Goods & Services

Pharmaceutical preparations for human use for the treatment and prevention of obesity, incontinence, cardiovascular diseases, central nervous system diseases and disorders, metabolic disorders, stroke, cancer, inflammation and inflammatory diseases, respiratory and infectious diseases, auto-immune diseases, solid organ transplant rejection, beta thalassemia and myelodysplastic syndromes, myeloproliferative diseases, myelofibrosis, leukemia, lymphoma, multiple myeloma, autoinflammatory disease, blood disease, tumors, multiple sclerosis, ulcerative colitis, arthritis, and musculoskeletal and skin diseases; Pharmaceutical preparations for human use, namely, antibiotics, anti-fungals, anti-virals, immunosuppressants, pharmaceutical antibodies, immunotherapies for the treatment of cancer, cytokine inhibitory drugs; Pharmaceutical preparations for human use that modulate the immune system; Pharmaceutical and biological preparations for human use for immunotherapy, namely T Cell therapy; Pharmaceutical preparations for human use, namely, stem cells for medical or clinical use; Pharmaceutical preparations for human use for the treatment or prevention of covid-19, coronavirus disease, and respiratory diseases and disorders; Pharmaceutical preparations for human use, namely, antivirals for treatment or prevention of covid-19, coronavirus disease, and respiratory diseases and disorders; Pharmaceutical preparations for human use, namely, monoclonal antibodies for medical use

Filing History

ABANDONMENT NOTICE E-MAILED - FAILURE TO RESPOND
Oct 16, 2025 MAB2
ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE
Oct 16, 2025 ABN2
APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED
Jun 30, 2025 XELG
APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED
Jun 30, 2025 XELR
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Apr 3, 2025 GNRN
NON-FINAL ACTION E-MAILED
Apr 3, 2025 GNRT
SU - NON-FINAL ACTION - WRITTEN
Apr 3, 2025 CNRT
STATEMENT OF USE PROCESSING COMPLETE
Mar 13, 2025 SUPC
CASE ASSIGNED TO INTENT TO USE PARALEGAL
Mar 13, 2025 AITU
USE AMENDMENT FILED
Jan 9, 2025 IUAF
TEAS STATEMENT OF USE RECEIVED
Jan 9, 2025 EISU
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Nov 12, 2024 TCCA
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Nov 12, 2024 CHAN
TEAS CHANGE OF OWNER ADDRESS RECEIVED
Nov 12, 2024 COAR
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Jul 11, 2024 EXRA
SOU EXTENSION 2 GRANTED
Jul 11, 2024 EX2G
SOU EXTENSION 2 FILED
Jul 11, 2024 EXT2
SOU TEAS EXTENSION RECEIVED
Jul 11, 2024 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Jan 12, 2024 EXRA
SOU EXTENSION 1 GRANTED
Jan 10, 2024 EX1G
SOU EXTENSION 1 FILED
Jan 10, 2024 EXT1
SOU TEAS EXTENSION RECEIVED
Jan 10, 2024 EEXT
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Jul 11, 2023 NOAM
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
May 16, 2023 NPUB
PUBLISHED FOR OPPOSITION
May 16, 2023 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Apr 26, 2023 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Apr 10, 2023 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Apr 7, 2023 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Apr 7, 2023 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Apr 7, 2023 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Oct 7, 2022 GNRN
NON-FINAL ACTION E-MAILED
Oct 7, 2022 GNRT
NON-FINAL ACTION WRITTEN
Oct 7, 2022 CNRT
ASSIGNED TO EXAMINER
Sep 29, 2022 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Apr 22, 2022 NWOS
NEW APPLICATION ENTERED
Apr 21, 2022 NWAP